Patient-reported resilience associated with outcomes after HCT
the ONA take:
Among long-term survivors of hematopoetic celltransplantation (HCT), patient-reported resilience is independently associated with health and psychosocial outcomes, according to a recent study published online ahead of print in Cancer.
Researchers led by Abby Rosenberg, MD, MS, of the Seattle Children’s Hospital observed 4,643 adult survivors of HCT as part of the annual Fred Hutchinson Cancer Research Center (FHCRC) post-transplant survivorship survey from July 2013 to June 2014.
The survey included patient-reported health and functional status as well as instruments that assessed psychosocial outcomes such as the 10-item Connor-Davidson Resilience scale, the Posttraumatic Growth Inventory, and the Cancer and Treatment Distress measure. Among those patients, 1,823 (39%) responded after a single mailing and subsequent reminder letter. Median age was 59 years and 52.5% of patients were male.
The researchers found that lower patient-reported resilience was associated with chronic graft-versus-host disease of higher severity, lower performance scores, missing work for health reasons, and permanent disability.
Upon adjusting for demographic and health characteristics, lower patient-reported resilience scores showed higher odds of having psychological distress as well as being in the lowest quartile for mental health-related quality of life.
“Future studies must determine whether interventions can bolster resilience and improve survivorship outcomes,” the authors concluded.
Among long-term survivors of hematopoetic cell transplantation (HCT), patient-reported resilience is independently associated with outcomes.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|